scholarly journals Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial

2018 ◽  
Vol 15 (1) ◽  
Author(s):  
Leila Sadat Bahrami ◽  
Seyed Hashem Sezavar Seyedi Jandaghi ◽  
Leila Janani ◽  
Mina Pahlavan ◽  
Seyed Mostafa Arabi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Randomized Clinical Trial ◽  
Vitamin D Supplementation ◽  
Heat Shock Protein 60

scholarly journals Elevated Heat Shock Protein 60 Levels Are Associated With Higher Risk of Coronary Heart Disease in Chinese

Circulation ◽  
2008 ◽  
Vol 118 (25) ◽  
pp. 2687-2693 ◽  
Author(s):  
Xiaomin Zhang ◽  
Mei'an He ◽  
Longxian Cheng ◽  
Ying Chen ◽  
Li Zhou ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Heat Shock Protein 60

scholarly journals Joint Effects of Antibody to Heat Shock Protein 60, Hypertension, and Diabetes on Risk of Coronary Heart Disease in Chinese

2008 ◽  
Vol 54 (6) ◽  
pp. 1046-1052 ◽  
Author(s):  
Xiaomin Zhang ◽  
Mei-An He ◽  
Longxian Cheng ◽  
Li Zhou ◽  
Hesong Zeng ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Simultaneous Occurrence ◽  
Heat Shock Protein 60 ◽  
Joint Effects ◽  
Chd Risk ◽  
High Concentrations ◽  
Chd Risk Factors

Abstract Background: Several studies have suggested an association between antibody to human heat shock protein 60 (anti-Hsp60) and coronary atherosclerosis, but the results have been inconsistent. The aim of this study was to investigate the association between anti-Hsp60 and coronary heart disease (CHD) and to determine whether anti-Hsp60, hypertension, and diabetes have joint effects on CHD risk. Methods: We measured the concentrations of anti-Hsp60 in 1003 CHD patients and 1003 age- and sex-matched control subjects without CHD events. Results: Concentrations of anti-Hsp60 were significantly higher in CHD patients than in controls. Increasing concentrations of anti-Hsp60 were significantly associated with higher risk of CHD (P for trend <0.0001) and with increasing severity of CHD as assessed by number of diseased vessels detected with angiography [odds ratio (OR) 3.67, 95% CI 1.56–8.64, P = 0.003] after multivariate adjustment for traditional CHD risk factors. There were strong joint effects of high concentrations of anti-Hsp60 and hypertension (OR 5.17, 95% CI 3.95–6.75, P < 0.0001) and diabetes (OR 6.49, 95% CI 4.52–9.33, P < 0.0001) on CHD risk; simultaneous occurrence of high anti-Hsp60 concentrations, hypertension, and diabetes conferred a dramatically higher risk of CHD (OR 20.99, 95% CI 12.50–35.24, P < 0.0001) in multivariate analyses. Conclusions: Anti-Hsp60 is independently associated with CHD risk, and a combination of high anti-Hsp60, hypertension, and diabetes is particularly detrimental for CHD risk.

scholarly journals Effects of vitamin D supplementation on red cell indices and cytokines in patients with thalassemia: An open-label randomized clinical trial

2019 ◽  
pp. 170-179
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Randomized Clinical Trial ◽  
Thalassemia Major ◽  
Vitamin D Supplementation ◽  
Beta Thalassemia ◽  
Red Cell ◽  
Open Label ◽  
Hematological Indices ◽  
Red Cell Indices

Background and aim Deficiency of vitamin D is known as a health problem all over the world and a recognized clinical complication of beta thalassemia patients. Vitamin D acts as a hormone at the nuclear receptor rendering it a beneficial medication for a number of diseases. It is believed that vitamin D is important in the modulation of the inflammation system by regulating the formation of inflammatory cytokines and immune cells. This study aimed to investigate the effect of vitamin D supplementation on the red cell indices and cytokines levels in patients with beta thalassemia major, in an open label randomized clinical trial. Patients and Methods: this study performed an open-label randomized clinical trial in patients with beta thalassemia major. Forty-six patients completed the eight weeks clinical trial and were allocated to administer oral vitamin D3 supplement of 100,000 IU every two weeks as an add-on treatment. During the study, hematological indices, serum iron, ferritin, vitamin D, calcium and inflammatory markers (interleukin-6, interleukin-2 and interleukin-10) were evaluated before (at baseline) and after vitamin D supplementation for 8 weeks. Results: Vitamin D3 supplements significantly decreases interleukin-6 levels and elevates the serum levels of anti-inflammatory cytokines IL-2 and IL-10, it also significantly reduced serum ferritin level, but it did not alter the hematological indices. Conclusion: Our results suggest that administration of vitamin D has a potential anti-inflammatory role in beta thalassemia patients and reduces serum ferritin levels, which may reduce the burdens of iron overload in thalassemia patients.

Sign in / Sign up

Export Citation Format

Share Document